Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Chiarle

Showing results (131-140 of 156) with videos related to

Pageof 16
Sort By:
Leukemia|October 18, 2024
Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistanceClarissa Corinaldesi, Antony B Holmes, Gaia Martire, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 30, 2016
Comprehensive population-based genome sequencing provides insight into hematopoietic regulatory mechanismsMichael H Guo, Satish K Nandakumar, Jacob C Ulirsch, et al.
Cell|April 7, 2015
The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivoFlorian A Karreth, Markus Reschke, Anna Ruocco, et al.
Iscience|April 25, 2025
Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphomaAlessandra Rossi, Saveria Mazzara, Dorotea Salemi, et al.
Cell Stem Cell|January 29, 2021
Dissecting ELANE neutropenia pathogenicity by human HSC gene editingShuquan Rao, Yao Yao, Josias Soares de Brito, et al.
Cancer Cell|October 11, 2017
Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2α Scaffolding FunctionFederico Gulluni, Miriam Martini, Maria Chiara De Santis, et al.
Biorxiv : the Preprint Server for Biology|April 25, 2024
Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cellsTomasz Grzywa, Naveen Mehta, Benjamin Cossette, et al.
Blood|July 8, 2022
Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphomaJacob D Soumerai, Allison Rosenthal, Shannon Harkins, et al.
Blood Advances|October 9, 2021
Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphomaChiara Pighi, Taek-Chin Cheong, Mara Compagno, et al.
Lancet (London, England)|May 30, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trialGeorg Lenz, Marek Trněný, John M Burke, et al.
Pageof 16

Showing results (131-140 of 156) with videos related to

Sort By:
Pageof 16
Leukemia|October 18, 2024
Single-cell transcriptomics of pediatric Burkitt lymphoma reveals intra-tumor heterogeneity and markers of therapy resistanceClarissa Corinaldesi, Antony B Holmes, Gaia Martire, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 30, 2016
Comprehensive population-based genome sequencing provides insight into hematopoietic regulatory mechanismsMichael H Guo, Satish K Nandakumar, Jacob C Ulirsch, et al.
Cell|April 7, 2015
The BRAF pseudogene functions as a competitive endogenous RNA and induces lymphoma in vivoFlorian A Karreth, Markus Reschke, Anna Ruocco, et al.
Iscience|April 25, 2025
Downregulation of rRNA synthesis by BCL-2 induces chemoresistance in diffuse large B cell lymphomaAlessandra Rossi, Saveria Mazzara, Dorotea Salemi, et al.
Cell Stem Cell|January 29, 2021
Dissecting ELANE neutropenia pathogenicity by human HSC gene editingShuquan Rao, Yao Yao, Josias Soares de Brito, et al.
Cancer Cell|October 11, 2017
Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2α Scaffolding FunctionFederico Gulluni, Miriam Martini, Maria Chiara De Santis, et al.
Biorxiv : the Preprint Server for Biology|April 25, 2024
Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cellsTomasz Grzywa, Naveen Mehta, Benjamin Cossette, et al.
Blood|July 8, 2022
Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphomaJacob D Soumerai, Allison Rosenthal, Shannon Harkins, et al.
Blood Advances|October 9, 2021
Frequent mutations of FBXO11 highlight BCL6 as a therapeutic target in Burkitt lymphomaChiara Pighi, Taek-Chin Cheong, Mara Compagno, et al.
Lancet (London, England)|May 30, 2026
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trialGeorg Lenz, Marek Trněný, John M Burke, et al.
Pageof 16